Moleculin Biotech, Inc. (MBRX) intrinsic value & 10-year financials
Moleculin Biotech, Inc. (MBRX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue reached to $0, with an average return on invested capital of -391.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.28
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -391.6%
- Free cash flow (FY2025)
- -$22.7M
MBRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$33.6M | — | -$22.7M | — | -597.1% |
| FY2024 | $0 | -$21.8M | — | -$23.9M | — | -1053.8% |
| FY2023 | $0 | -$29.8M | — | -$24.2M | — | -478.8% |
| FY2022 | $0 | -$29.0M | — | -$27.7M | — | -349.5% |
| FY2021 | $0 | -$15.9M | — | -$19.0M | — | -421.5% |
| FY2020 | $0 | -$17.4M | — | -$18.1M | — | -502.5% |
| FY2019 | $0 | -$13.2M | — | -$17.2M | — | -337.0% |
| FY2018 | $0 | -$11.9M | — | -$12.6M | — | -95.7% |
| FY2017 | $0 | -$9.8M | — | -$7.4M | — | -53.9% |
| FY2016 | $0 | -$3.9M | — | -$3.8M | — | -26.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Moleculin Biotech, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Moleculin Biotech, Inc. has historically struggled to out-earn its cost of capital, averaging just -21.3% ROIC.
Moleculin Biotech, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Moleculin Biotech, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.